Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Chokeberry (Aronia melanocarpa) has garnered scientific interest for its potential cardiovascular benefits, including its role in supporting or treating arteriosclerosis. Several preclinical and a limited number of clinical studies suggest that chokeberry’s high content of polyphenols, particularly anthocyanins and flavonoids, may contribute to vascular health. These compounds exhibit strong antioxidant and anti-inflammatory properties, which help reduce oxidative stress and endothelial dysfunction—both of which are key contributors to the development and progression of arteriosclerosis. A few small-scale human studies have shown that chokeberry extract supplementation can lower blood pressure, reduce LDL cholesterol, and improve markers of endothelial function in people at risk of cardiovascular disease. For example, a 2007 randomized, placebo-controlled trial found that patients with metabolic syndrome who took chokeberry extract for two months experienced significant reductions in total cholesterol, LDL cholesterol, and blood pressure. Animal studies have also demonstrated reduced plaque formation and improved vascular function with chokeberry supplementation. However, while initial results are promising and provide a mechanistic rationale for chokeberry’s use in arteriosclerosis, large-scale, high-quality clinical trials are lacking. Most human studies are small, short-term, and often use varying preparations and dosages. Therefore, while there is scientific evidence to suggest potential benefits, the overall strength of evidence is modest (rated 2/5), and chokeberry should not be considered a primary treatment for arteriosclerosis but may be a useful adjunct to lifestyle and standard medical therapy.

More about chokeberry
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by chokeberry

Products containing chokeberry